2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 016

Genetic Susceptibility Loci for Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Syndrome
Abstract Number: 017

MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Abstract Number: 018

Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
Abstract Number: 019

Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Abstract Number: 020

Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies
Abstract Number: 021

Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies
Abstract Number: 022

Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Abstract Number: 023

Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Abstract Number: 024

Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Abstract Number: 025

HLA Genetic Signatures Associated with Inflammatory Sub-type in Juvenile Localized Scleroderma
Abstract Number: 026

Allogeneic Hematopoietic Cell Transplantation (HCT) in the National Institutes of Health (NIH)’s Deficiency of Adenosine Deaminase 2 (DADA2) Patient Cohort
Abstract Number: 027

Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition
Abstract Number: 028

A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Abstract Number: 029

Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Abstract Number: 030

The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].